Physician profile
Benjamin D Biehl
NPI 1336377084
$1,363.18
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $108 · 2021: $215 · 2022: $372 · 2023: $283 · 2024: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $313.92 | 2019-2024 | Prolia, Evenity |
| Novo Nordisk INC | $151.45 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $138.72 | 2019-2024 | |
| Lilly USA, LLC | $126.92 | 2021-2024 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $90.23 | 2019-2024 | |
| Mylan Specialty L.P. | $66.30 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $64.29 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.39 | 2021-2024 | Xifaxan |
| Philips North America LLC | $50.52 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.79 | 2022 | |
| Abbvie INC. | $43.74 | 2021-2023 | Qulipta |
| Organon LLC | $41.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.99 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $26.62 | 2021-2023 | |
| Glaxosmithkline, LLC. | $25.70 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.63 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $16.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.37 | 2022 | |
| Merck Sharp & Dohme LLC | $14.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Biehl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.